Company: SMNR
Filing Date: 2025-08-22
Form Type: DEFA14A
Source: 0001213900-25-079507
Chunk: 1

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-22
Form: DEFA14A
Chunk 1
---
 since last report)</div>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☒ | Written communication pursuant                        
 to Rule 425 under the Securities Act (17 CFR 230.425) |

| ☐ | Soliciting material pursuant                              
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement communications                                        
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencements communications                                       
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

| Title                                                                                                  
 of each class                                                                                          |     | Trading   
 Symbol(s) |     | Name                
 of each exchange    
 on which registered |
| Units,                                                                                                 
 each consisting of one Class A ordinary share and one redeemable warrant                               |     | DNQUF     |     | Pink                
 Current             |
| Class                                                                                                  
 A ordinary shares, par value $0.0001 per share                                                         |     | DNQAF     |     | OTCQB               |
| Warrants,                                                                                              
 each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share |     | DNQWF     |     | OTCQB               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On August 20, 2025, Denali Capital Acquisition Corp., a Cayman Islands exempted company (the “Company” or “Denali”), entered into a Securities Purchase Agreement (the